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Introduction
This conference, “Beyond Secondary Prevention: Identifying
the High-Risk Patient for Primary Prevention,” which was the
fifth in a series of prevention conferences sponsored by the
American Heart Association (AHA), was held October 26–
28, 1998, in San Francisco, Calif. The need for this confer-
ence was precipitated by the remarkable advances in medical
therapies for the prevention of coronary heart disease (CHD).
The AHA has already set forth guidelines for aggressive
medical therapy in patients with established CHD (secondary
prevention). The major issue under consideration at this
conference was the development of strategies to identify
high-risk patients without established CHD who are candi-
dates for aggressive medical therapies for primary prevention.
Therefore, a central theme for the conference was the empha-
sis on establishing a prognosis for high-risk patients without
clinical evidence of CHD. Three writing groups were estab-
lished to report on the following areas: (1) medical office
assessment, (2) tests for silent and inducible ischemia, and
(3) noninvasive tests of atherosclerotic burden. Each working
group reviewed research on existing risk-assessment strate-
gies relevant to the prediction of risk in patients without
clinical evidence of CHD.
The key findings of each working group are presented in
this Executive Summary of the conference. The full confer-
ence report with references is available online at http://
circ.ahajournals.org/ in the January 4/11, 2000, issue of
Circulation. The recommended strategies will assist in ex-
panding preventive therapies, including lipid lowering, blood
pressure control, smoking cessation, diet, and exercise, to
patients at high risk for developing CHD. The following
briefly summarizes the major conclusions of the conference.
In the development of the Prevention V report, Writing Group
I outlined a strategy for initial risk assessment of the asymptom-
atic patient to obtain an estimate of absolute risk. On the basis of
standard risk factors and related risk correlates, the concept was
set forth that asymptomatic patients can be placed into 1 of 3 risk
categories: low risk, intermediate risk, and high risk (Table 1).
Low-risk patients can be encouraged to adhere to healthy life
habits. High-risk patients can directly enter a regimen of aggres-
sive risk reduction through a combination of nondrug and drug
regimens. Patients at intermediate risk become candidates for
further risk stratification through noninvasive procedures that
test for the presence of myocardial ischemia or coronary athero-
sclerotic burden. The purpose of the latter procedures is to assist
the physician in better defining absolute risk of intermediate-risk
patients. Although these noninvasive procedures have tradition-
ally been used for diagnosis of coronary artery disease for the
purpose of invasive intervention, the emphasis of Prevention
Conference V was on their use to predict future major coronary
events (unstable angina and myocardial infarction). This shift in
emphasis from diagnosis to prognosis is illustrated by differ-
ences in terminology between the 2 activities (Table 2).
Writing Group II examined the potential of techniques for
determining subclinical myocardial ischemia for risk prognosti-
cation in intermediate-risk patients. A review of the literature
indicated that exercise electrocardiography (ECG) has indepen-
dent predictive power beyond standard risk factors for patients
of this type. Other techniques to detect subclinical ischemia may
have utility for this purpose in selected patients, although
literature related to this issue is sparse.
Writing Group III examined techniques used to estimate
atherosclerotic burden for the purpose of risk prognostica-
tion. The ankle/brachial blood pressure index (ABI)
emerged as a powerful, independent predictor of future
coronary events. Several reports further indicate that
measures of carotid intimal-medial thickness (IMT) by
B-mode sonography provide an independent assessment of
coronary risk. Finally, measures of coronary calcium by
computerized tomography (CT) show a high correlation
with extent of coronary atherosclerosis. Furthermore, pre-
liminary studies suggest that coronary calcium scores
provide an independent estimate of future coronary events;
however, available studies are insufficient to define the
magnitude of independent prediction. Overall, noninvasive
procedures for assessing myocardial ischemia and athero-
sclerotic burden promise to improve the accuracy of risk
prognostication for patients found to be at intermediate
risk by office-based assessment.
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Writing Group I: Medical Office Assessment
Writing Group I examined methods for estimating total cardio-
vascular risk in the medical office. The emphasis of this group
was on the known risk factors for CHD. For some patients, the
presence of multiple risk factors is sufficient to confer a
high-risk status, and additional noninvasive testing for coronary
atherosclerotic burden or for subclinical myocardial ischemia
will be unnecessary. In patients found to be at intermediate risk,
however, additional testing may be indicated to better stratify
risk. Techniques for office assessment include history, physical
examination, laboratory testing, and ECG. The focus of the
examination is on detection of risk factors that can either be
directly modified or that will modify the overall intensity of
risk-reduction therapies. Patients should be examined for the
presence of risk factors listed in Table 3. The major causal risk
factors—cigarette smoking, elevated blood pressure, elevated
serum total cholesterol (and low-density lipoprotein [LDL]
cholesterol in particular), low high-density lipoprotein (HDL)
cholesterol, and diabetes—account for '50% of the variability
in risk in high-risk populations and explain up to 90% of the
excess population risk for CHD. A patient’s age is a powerful
indicator of absolute risk because it reflects the total burden of
coronary atherosclerosis that has accumulated; the probability of
suffering a major coronary event (unstable angina or myocardial
infarction) is highly correlated with total plaque burden. Condi-
tional risk factors are those that have been correlated with CHD
risk, but their quantitative relation to major coronary events
remains to be defined adequately in large prospective studies.
The predisposing risk factors contribute to the development of
the causal and conditional risk factors. Two of these, obesity and
physical inactivity, have such a strong relationship with the
development of cardiovascular disease (CVD) that they are
designated as major risk factors by the AHA. Abnormalities in
the resting ECG (nonspecific ST-segment changes and left
ventricular hypertrophy) also carry predictive power and can be
called risk factors.
Categories of Risk
To determine the risk for CHD, the coronary end point must
be specified. The Framingham Heart Study traditionally
identifies total CHD as its end point; this includes stable
angina pectoris, major coronary events (unstable angina and
myocardial infarction), and coronary death. Recently, Fra-
mingham investigators have distinguished between total
CHD and hard CHD, the latter consisting of major coronary
events and coronary death. Hard CHD typically is the primary
end point in clinical trials of risk factor reduction. Risk
estimates essentially are of 2 types, absolute risk and relative
risk. Absolute risk is the probability of developing CHD in a
finite period, whereas relative risk is the ratio of absolute risk
for a patient over a standard risk. The latter can be either the
average risk or the low risk associated with an absence of risk
factors.
TABLE 1. Risk Stratification of Asymptomatic Persons




*Quantitative definitions of risk categories based on probabilities of devel-
oping a disease await future analysis of efficacy, safety, and cost-effectiveness
for specific risk-reduction interventions.
TABLE 2. Two Approaches to Cardiovascular Evaluation
I. Diagnosis of existing disease
A. Diagnostic sensitivity: percentage of patients with disease who have
an abnormal test result
B. Diagnostic specificity: percentage of patients without disease who
have a normal test result
C. Diagnostic value of abnormal test: percentage of patients with an
abnormal test result who have existing disease
D. Diagnostic value of normal test: percentage of patients with a normal
test result who do not have existing disease
II. Prognosis for future coronary events
A. Absolute risk: probability of developing events in a finite period
B. Relative risk: absolute risk of high-risk group/absolute risk of low-risk
group




Elevated serum cholesterol (or LDL cholesterol)
Alternative: elevated apolipoprotein B
Low HDL cholesterol
Diabetes mellitus
Coronary plaque burden as a risk factor
Age











Overweight and obesity (especially abdominal obesity)†
Physical inactivity†
Male sex
Family history of premature CHD
Socioeconomic factors




*These factors are considered conditional risk factors when serum levels are
abnormally high.
†Obesity and physical inactivity are counted as major risk factors by the AHA.
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In the past decade, the concept has evolved that the intensity
of risk factor management should be adjusted by the severity
of risk. This concept has been adopted in the guidelines of the
National Cholesterol Education Program, the joint European
societies, and other organizations. Global risk assessment is
the estimation of absolute risk based on the summation of
risks contributed by each risk factor. Several methods have
been used to sum risks. Writing Group I favored a method
recently proposed by Framingham researchers in which the
continuous relationship between risk factor intensity and
coronary risk is used. Framingham scoring uses only the
“standard” risk factors (smoking, blood pressure, serum
cholesterol, HDL cholesterol, blood glucose, and age). Con-
ditional and predisposing risk factors are not used in the
Framingham risk equation because of lack of evidence of a
strong, independent contribution to CHD risk. The writing
group nonetheless stressed that several of the conditional and
predisposing risk factors undoubtedly contribute to the devel-
opment of CHD. Thus, the detection and even therapeutic
modification of these risk factors may be appropriate in some
patients.
Short-Term Versus Long-Term Risk
Global assessment for short-term (#10 years) risk is the foun-
dation of guidelines of the joint European societies. European
recommendations defined a high-risk state as a 10-year absolute
risk for developing CHD of $20%. This level of risk was
identified as one that justifies management of risk factors in the
clinical setting, particularly for the pharmacological control of
elevated blood pressure and cholesterol. Writing Group I was
attracted to the European concept of applying increased intensity
of therapy to a category of patients at high short-term risk.
However, the writing group was reluctant to embrace the
specific European definition of high risk. This arbitrary defini-
tion derives from 3 factors: efficacy, safety, and cost of therapy.
Because efficacy and safety of pharmacological therapy have
improved progressively, the dominant factor in the definition
becomes cost-effectiveness. The writing group hesitated to adopt
a general definition of high risk without the availability of
extensive cost-effectiveness analyses.
Moreover, the writing group also expressed reluctance to
allow short-term risk estimates to drive all treatment decisions.
Patients who have intermediate risk in the short term may still be
at high risk in the long term. To exclude such patients from
clinical management of risk factors may not be prudent. For
example, any single risk factor can produce cumulative damage
and thus lead to premature clinical syndromes if left untreated
for many years. Therefore, most members of the writing group
expressed the opinion that every causative risk factor deserves
modification under physician supervision once it has reached a
categorical level (Table 4). Clinical judgment is required as to
whether risk-factor reduction is best carried out with nondrug or
drug therapies.
Finally, Writing Group I emphasized that risk assessment
in the medical office is the backbone of global risk assess-
ment. Even if risk estimates can be improved by noninvasive
measures of coronary atherosclerosis, the selection of patients
for noninvasive testing should issue from office-based risk
assessment. Patients found to be at high risk through office-
based assessment need not proceed to noninvasive testing. On
the other hand, some asymptomatic patients who appear to be
at intermediate risk on the basis of office assessment could be
elevated to the high-risk category by the finding of advanced
subclinical atherosclerosis or myocardial ischemia.
Writing Group II: Tests for Silent and
Inducible Ischemia
Writing Group II addressed the question of whether tests that
assess silent ischemia or inducible ischemia add to prognostic
information gained from standard risk factors in asymptom-
atic patients without known coronary disease. The tests
reviewed included exercise ECG, exercise and pharmacolog-
ical (stress) echocardiogram (echo), exercise and pharmaco-
logical myocardial perfusion imaging, ambulatory ECG mon-
itoring, and positron emission tomography (PET). These
noninvasive tests detect myocardial ischemia associated with
obstructive coronary artery disease. Their greatest application
to date has been diagnostic, in the evaluation of patients with
symptoms of angina or a previous clinical manifestation of
CHD. A limitation of all methods used to detect stress
(exercise or pharmacologically induced) myocardial ischemia
is their dependence on the presence of flow-limiting coronary
stenosis. As with all diagnostic studies, their predictive value
is dependent on the prevalence of disease in the population
tested. Also central to the Writing Group II discussions was
the recognition that the majority of future events among
patients with CHD are related to severity of obstruction,
plaque instability, and total atherosclerotic burden. The group
was specifically concerned with delineating the prognostic
information available from these tests that could contribute
toward identifying patients at higher risk for major CHD-
related events.
Exercise ECG Testing
Among asymptomatic individuals, there is evidence that the
development of an ischemic ECG response at low workloads
of exercise testing is associated with a higher incidence of
future events such as angina pectoris, myocardial infarction,
and sudden death. However, the absolute risk of cardiac
events in these populations remains low.
The Multiple Risk Factor Intervention Trial (MRFIT)
reported a nearly 4-fold increase in 7-year coronary mortality
(7.6 versus 2.0 per 1000 person-years of risk) among middle-
aged men with an abnormal exercise ECG versus those with
a normal exercise ECG and suggested that the exercise ECG
might serve to identify high-risk men who could benefit from
risk factor reduction. There is a paucity of similar data
TABLE 4. Categorical Risk Factors
● Cigarette smoking (any current smoking)
● Hypertension (blood pressure $140/90 mm Hg)
● Elevated LDL cholesterol ($160 mg/dL)
● Low HDL cholesterol (,35 mg/dL)
● Diabetes mellitus (plasma glucose $126 mg/dL)
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regarding the use of the exercise ECG in women and the
elderly (age .75 years).
In the Lipid Research Clinics Coronary Primary Prevention
Trial, of 3775 asymptomatic hypercholesterolemic men, half of
whom were taking cholestyramine and half of whom were
taking placebo, there was a 5.7 times greater risk of death due to
coronary heart disease in the placebo group among those with a
positive exercise test result ($1-mm ST-segment depression or
elevation on exercise testing) than among those with a negative
test result. Overall, during a mean follow-up period of 7.4 years,
there was a 6.7% mortality rate in the group with a positive test
result versus 1.3% in the group with a negative test result.
The routine use of exercise ECG testing in completely
unselected asymptomatic populations before office screening
for risk cannot be recommended. In asymptomatic men .40
years of age with $1 risk factor, exercise testing may provide
useful information as a guide to aggressive risk factor
intervention or the need to evaluate further the cause of
myocardial ischemia. The role of exercise testing in women
and among the elderly (age .75 years) as a guide to




Stress echocardiography (SE) is based on the premise that
myocardial ischemia leads to left ventricular dyssynergy that can
be detected with 2-dimensional echo. Only limited data exist to
support the use of SE as a tool to elevate the intermediate-risk,
asymptomatic patient to a higher risk category. Also, the
addition of echocardiographic imaging to exercise ECG in
intermediate-risk patients increases the cost and complexity of
the examination. On the other hand, SE could be of value in the
assessment of women and elderly patients who fall into the
intermediate-risk category; nevertheless, additional studies are
needed to define its role for elevating such patients to the
high-risk category for primary prevention.
Exercise and Pharmacological Myocardial
Perfusion Imaging
Myocardial perfusion imaging has evolved as an important
clinical tool in the evaluation of patients with symptoms
suggestive of angina pectoris or its equivalents. An important
question is whether stress thallium scintigraphy can be a
useful addition to exercise ECG for determining risk for
major coronary events in intermediate-risk asymptomatic
patients. Limited data suggest incremental value for this
purpose in some populations. Such populations might include
postmenopausal women and elderly men (age .75 years), in
whom the use of exercise ECG testing is problematic.
Ambulatory ECG Monitoring
Because of the low sensitivity and specificity of ambulatory
ECG monitoring for the diagnosis of multiple coronary arteries
with .50% occlusion, published recommendations suggest that
it is an inaccurate modality for use as a guide in the selection of
patients for invasive procedures. The guidelines for use of
ambulatory ECG generated by the American College of Cardi-
ology/AHA Task Force consider that its use for detecting
myocardial ischemia in the asymptomatic individual is a class III
indication, ie, there is general agreement that it is not a useful test
in these circumstances. The value of ambulatory ECG monitor-
ing as a prognostic indicator of major coronary events in
intermediate-risk patients has not been adequately evaluated.
Whether it provides incremental information over that obtained
from a resting ECG is unknown.
Positron Emission Tomography
The basis for detecting myocardial ischemia by PET is the
detection of flow heterogeneity during maximal coronary
hyperemia, and significant ischemia is only detectable if
coronary stenosis is hemodynamically significant. Because
PET is insensitive for the detection of ,50% coronary
stenoses, its incremental prognostic power over exercise ECG
is doubtful. Moreover, the test is expensive. Therefore, it was
not considered to provide additional quantitative risk predic-
tion over exercise ECG in middle-aged asymptomatic men in
the intermediate-risk category. Whether it would be more
useful than exercise ECG in women or elderly men (.75
years) remains to be determined. Although significant issues
exist surrounding the cost-effectiveness of PET in the eval-
uation of asymptomatic patients at risk for CHD, preliminary
research suggests there may be future applications of this
technique in the detection of coronary endothelial dysfunc-
tion and the noninvasive monitoring of aggressive medical
therapy and risk factor modification.
Conclusions
Data are quite limited regarding the prognostic utility of
noninvasive measures of inducing myocardial ischemia in
apparently asymptomatic people. Very few prognostic studies
have included adequate numbers of asymptomatic people.
With the exception of exercise ECG testing in asymptomatic
men with increased cardiovascular risk profiles, few data
exist to support the use of the noninvasive testing modalities
discussed by Writing Group II to screen asymptomatic
populations for high-risk subclinical CHD. Future research
should investigate the role of these techniques in association
with global risk assessment to further define prognosis, guide
intensity of therapy, and monitor the effectiveness of risk-
intervention strategies.
Summary
The purpose of noninvasive testing for subclinical myocardial
ischemia is to detect patients who have been found to be at
intermediate risk by office-based risk assessment and identify
those who are candidates for more aggressive risk-reduction
therapies. Several studies in middle-aged men in this category
have documented that exercise ECG has independent power
for predicting major coronary events and may be a useful
adjunct in identifying high-risk patients who otherwise would
be classified as being at intermediate risk. On the other hand,
exercise ECG has little use in the routine screening of young
adults who as a group are at low risk for developing CHD in
the next decade. Furthermore, its predictive power in older
men (.75 years) and women is uncertain. Ambulatory ECG
apparently is less sensitive than exercise ECG for detecting
myocardial ischemia, and its use for risk adjustment cannot
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be recommended at this time. SE appears to add little
prognostic/diagnostic information to exercise ECG in middle-
aged men but may have utility for adjusting risk assessment
in women and older men (.75 years), in whom the predictive
power of exercise ECG is uncertain. The same can be said
regarding myocardial perfusion imaging. PET scanning may
detect myocardial ischemia in the presence of less severe
degrees of coronary atherosclerosis than can be detected by
exercise ECG; however, its lack of availability and high cost
seemingly do not justify PET scanning of intermediate-risk
patients whose exercise ECGs are normal.
Writing Group III: Noninvasive Tests of
Atherosclerotic Burden
Writing Group I considered the role of routine office-based
measures for assessment of global risk in asymptomatic
people. With the physician-directed office risk assessment as
a foundation, further risk stratification may be valuable,
especially when the risk estimate is neither clearly low risk
nor high risk (intermediate risk). For the intermediate-risk
patient, additional testing might include one or more nonin-
vasive measures of atherosclerotic burden.
Pathology studies document that the levels of “traditional”
risk factors are associated with the extent and severity of
atherosclerosis. However, at every level of risk factor expo-
sure, there is substantial variation in the amount of the
atherosclerosis. Thus, subclinical disease measurements, rep-
resenting the end result of risk exposures, may be useful in
improving CHD risk prediction.
Noninvasive tests such as carotid artery duplex scanning,
electron beam CT (EBCT), ultrasound-based endothelial func-
tion studies, ankle/brachial blood pressure ratios, and magnetic
resonance imaging (MRI) techniques offer the potential for
directly or indirectly measuring and monitoring atherosclerosis
in asymptomatic people. High-sensitivity testing for C-reactive
protein (hs-CRP) may also represent a measure of atherosclero-
sis “burden” and may therefore be considered another potential
marker of atherosclerotic disease risk.
Ankle/Brachial Blood Pressure Index
The ABI is a simple diagnostic test for lower-extremity
peripheral arterial disease (PAD). Among well-trained oper-
ators, test-retest reliability is excellent, and the validity of the
test for $50% stenosis in leg arteries is high (sensitivity
'90% and specificity '98%).
In population studies, people with a low ABI have been found
to have a considerably higher prevalence of CVD (defined as
history of myocardial infarction, coronary artery bypass graft,
stroke, or stroke surgery or other measures of clinical CVD, such
as angina or congestive heart failure) than those individuals with
a normal ABI. These data confirm that atherosclerosis is a
diffuse (ie, systemic) disease and that an abnormal ABI test (ie,
low ratio) will often be indicative of significant atherosclerosis in
other vascular beds. At least 3 studies have reported an increased
combined incidence of CVD morbidity and CVD mortality in
persons with PAD detected by ABI.
Conclusions
The ABI is a simple, inexpensive, noninvasive measure of
PAD. Many asymptomatic people $50 years of age will have
abnormal ABI values. Follow-up studies have shown that an
abnormal ABI provides incremental coronary and all-CVD
risk-assessment information over and above that provided by
traditional risk factors. The writing group concluded that the
ABI might be a useful addition to the assessment of CHD risk
in selected populations, especially in people aged 50 years
and older or those who appear to be at intermediate or higher
risk for CVD on the basis of traditional risk factor assess-
ment, such as cigarette smokers or individuals with diabetes
mellitus, who have a particularly high risk for PAD. If a
patient is found to have an abnormal ABI, this patient can be
elevated to a higher risk category. The high relative risk in
patients with abnormal ABIs is similar to that of patients who
qualify for the AHA secondary-prevention regimen.
B-Mode Ultrasound
B-mode ultrasound is a relatively inexpensive and safe
technique that can noninvasively visualize the lumen and
walls of selected arteries, including carotid, aorta, and fem-
oral arteries. B-mode ultrasound has been validated for the
measurement of IMT. Cross-sectional associations between
common carotid artery IMT and cardiovascular risk factors
have been demonstrated in several studies. Similarly, com-
mon carotid IMT has been associated with prevalent CVD in
cross-sectional studies. Furthermore, at least 4 published
studies found that carotid IMT measurement was a viable
predictor of the presence of coronary atherosclerosis and its
clinical sequelae. Thus, carotid IMT defined by noninvasive
B-mode ultrasound has been shown to be an independent risk
factor for CHD events and stroke.
Conclusions
Carotid artery B-mode ultrasound imaging is a safe, nonin-
vasive, and relatively inexpensive means of assessing sub-
clinical atherosclerosis. The technique can measure IMT, an
operational measure of atherosclerosis, in a valid and reliable
manner. The severity of carotid IMT is an independent
predictor of transient cerebral ischemia, stroke, and coronary
events such as myocardial infarction. The writing group
concluded that in asymptomatic individuals older than 45
years of age, carefully performed carotid ultrasound exami-
nation with IMT measurement can add incremental informa-
tion to traditional risk factor assessment. In experienced
laboratories, this test can now be considered for further
clarification of CHD risk assessment at the request of a
physician.
Coronary Calcium Scores in CAD
Risk Assessment
Calcification within the coronary arterial wall is a recognized
marker of atherosclerosis. EBCT and helical CT are highly
sensitive means of detecting coronary calcium and are being
intensively evaluated as noninvasive means of defining cor-
onary atherosclerotic disease and identifying the asymptom-
atic but high-risk CAD patient. There are, however, relatively
few prospective data linking coronary calcium scores with
risk of subsequent CHD events. Data concerning risk predic-
tion with EBCT in asymptomatic people (the primary focus
of the Prevention V conference) are sparse.
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The presence of coronary calcium correlates strongly with
coronary atherosclerosis. Because the severity of coronary ath-
erosclerosis (from pathological or angiographic studies) is well
known to be associated with risk of coronary events, coronary
calcium scores likewise should correlate with risk for coronary
events. However, the extent to which coronary calcium scores
predict coronary events independently of the traditional coronary
risk factors needs additional study. This latter uncertainty must
be weighed against the costs of measurement and the risk that
the results of the tests may create enough concern for patients
and their physicians to lead to inappropriate and invasive
coronary evaluation. Because of these uncertainties and con-
cerns, the writing group was reluctant to advocate the use of
EBCT for routine risk assessment in spite of the promise of the
technique. The greatest potential for coronary calcium scores
would appear to be in the detection of advanced coronary
atherosclerosis in patients at apparently intermediate risk. Con-
versely, low or absent coronary calcium scores may prove
valuable in determining a low CAD event risk. Some clinicians
and researchers currently recommend use of the coronary cal-
cium score in risk assessment in these ways. However, the
majority opinion of the writing group was that until there is more
definitive information about the additive value of calcium scores
in the asymptomatic individual, coronary calcium measurement
should not be recommended for routine risk assessment in
asymptomatic populations. Selected use of coronary calcium
scores when a physician is faced with a patient with intermediate
coronary disease risk may be appropriate.
MRI and Atherosclerotic Disease
There has been increasing awareness of the importance of
composition of atherosclerotic plaque as a major risk factor
for acute coronary syndromes. MRI has been shown to
characterize tissue noninvasively in many different study
systems. Therefore, research has begun to focus on the use of
in vivo MRI to evaluate the vessel wall in several animal
models and in humans.
Conclusions
MRI is a promising research tool, but its use appears limited to
only a small number of research laboratories at this time. The
writing group concluded that MRI is not ready for application in
the identification of patients at high risk for CAD.
Endothelial Function Studies and CAD Risk
The most frequently used endothelium-directed vasodilator
stimulus is an increase in blood flow. Investigators are still
seeking to improve the methods for ultrasonographic analysis
of brachial artery vasomotion. To achieve optimal results,
careful attention must be paid to details such as minimization
of patient stress or discomfort, recent fat intake, and cigarette
smoking and other transient exposures that may alter sympa-
thetic tone. The technique is skill and labor intensive and is
not yet easily applied to the routine clinical domain.
Conclusions
Although the assessment of endothelial function, as measured
most typically by flow-mediated brachial artery vasodilation,
is a promising technique that may reflect an independent
measure of CVD risk, additional prospective research is
needed to demonstrate that this technique can truly add to
standard CVD risk prediction. In addition, standardization
and improvement of the measurement technique are needed
before this modality can become a part of routine clinical
assessment of CVD risk.
hs-CRP as a Marker of CAD Risk
A number of blood factors have received attention as poten-
tial new markers of CAD and all-CVD risk. The list of
potential candidates includes total plasma homocysteine
(tHcy), lipoprotein(a) [Lp(a)], fibrinolytic function (as as-
sessed by tissue plasminogen activator and plasminogen
activator inhibitor-1 antigens), and inflammatory parameters
such as fibrinogen and CRP. Many of these markers are not
yet considered applicable for routine clinical CVD risk
assessment because of (1) lack of measurement standardiza-
tion [eg, Lp(a) testing, fibrinogen, and tHcy], (2) lack of
consistency in epidemiological findings from prospective
studies with CVD end points [eg, data for Lp(a) and tHcy are
inconsistent], and (3) lack of evidence that the novel marker
adds to risk prediction over and above that already achievable
through the use of established cardiovascular risk factors.
Laboratory evidence and findings from pathological studies
suggest that the inflammatory process plays an important part
in the atherosclerotic process. CRP is a sensitive marker for
vascular inflammation, and it has been suggested that hs-CRP
may provide a novel method to assess CVD risk that is
additive to the assessment of traditional CVD risk factors.
Conclusions
hs-CRP has been shown to predict future coronary events in
several prospective studies and may add to the predictive
value of lipid testing alone. hs-CRP testing may become
commercially available in the near future. The writing group
concluded that additional studies of this approach to risk
prediction are warranted and should be undertaken before this
measurement can be advised for addition to the routine
assessment of coronary risk.
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